

# REVIEWER CREDITS

## PEER REVIEW CERTIFICATE

**Desdiani Desdiani**

*[Faculty of Medicine Universitas Sultan Ageng Tirtayasa, Indonesia]*

performed the following activity:

**Year 2022**

"The Journal of Infection in Developing Countries": **1** peer review;

*All data reported above have been registered in our service by Desdiani Desdiani since 2016 and [validated by ReviewerCredits](#).*

Total registered reviews: **1**

05/12/2022

**RC**

*The ReviewerCredits Team*



## [JIDC] Article Review Request

---

Dari: Marina Pekmezovic (marinapekmezovic@gmail.com)

Kepada: desdiani@ymail.com

Tanggal: Selasa, 27 September 2022 pukul 22.15 GMT+7

---

\*\*\* THIS IS AN AUTOMATED EMAIL -- DO NOT REPLY \*\*\*

Desdiani Desdiani:

I believe that you would serve as an excellent reviewer of the manuscript, "COVID-19-associated pulmonary aspergillosis (CAPA): Identification of *Aspergillus* species and determination of antifungal susceptibility profiles: Detection of *Aspergillus* species associated with COVID-19," which has been submitted to The Journal of Infection in Developing Countries. The submission's abstract is inserted below, and I hope that you will consider undertaking this important task for us.

Please log into the journal web site by 2022-10-04 to indicate whether you will undertake the review or not, as well as to access the submission and to record your review and recommendation.

The review itself is due 2022-10-18.

Submission URL: <https://jidc.org/index.php/journal/reviewer/submission?submissionId=17238&reviewId=26541&key=LciZhGU6>

*The Journal of Infection in Developing Countries is member of ReviewerCredits. Completing the peer-review you are invited to, will qualify you to the third-party certification provided by this organization and assign you credits, which may be used on ReviewerCredits online store. Register now a free ReviewerCredits account and get ready to start. Find out more [here](#).*

Thank you for considering this request.

Marina Pekmezovic  
marinapekmezovic@gmail.com

-- ARTICLE DETAILS --

"COVID-19-associated pulmonary aspergillosis (CAPA): Identification of *Aspergillus* species and determination of antifungal susceptibility profiles: Detection of *Aspergillus* species associated with COVID-19"

Abstract

**Introduction:** Among the co-infectious agents in COVID-19 patients, *Aspergillus* species cause invasive pulmonary aspergillosis (IPA). IPA is difficult to diagnose and is associated with high morbidity and mortality. This study aimed to identify *Aspergillus* spp from sputum and tracheal aspirate (TA) samples of COVID-19 patients and to determine their antifungal susceptibility profiles.

**Methodology:** A total of 50 patients with COVID-19 hospitalized in their intensive care units were included in the study. Identification of *Aspergillus* isolates was performed by phenotypic and molecular methods. ECMM/ISHAM consensus criteria were used for IPA case definitions. The antifungal susceptibility profiles of isolates were determined by the microdilution method.

**Results:** *Aspergillus* spp was detected in 35 (70%) of the clinical samples. Among the *Aspergillus* spp, 20 (57.1%) *A. fumigatus*, 6 (17.1%) *A. flavus*, 4 (11.4%) *A. niger*, 3 (8.6%) *A. terreus*, and 2 (5.7%) *A. welwitschiae* were identified. In general, *Aspergillus* isolates were susceptible to the tested antifungal agents. In the study 9 patients (18%) were diagnosed with possible IPA, 11 (22%) patients were diagnosed with probable IPA, and 15 (30%) patients were diagnosed with *Aspergillus* colonization according to the used algorithms. Serum GM antigen positivity was found in 11 (55%) of the patients diagnosed with IPA (n=20).

*Conclusions:* Our results provide data on the incidence of IPA, identification of *Aspergillus* spp, and its susceptibility profiles in critically ill COVID-19 patients. Prospective studies are needed for a faster diagnosis or antifungal prophylaxis to manage the poor prognosis of IPA and reduce the risk of mortality.

--

The Journal of Infection in Developing Countries

## [JIDC] Article Review Request

---

Dari: JIDC Central Office (info@jdc.org)

Kepada: desdiani@ymail.com

Tanggal: Sabtu, 8 Oktober 2022 pukul 03.05 GMT+7

---

\*\*\* THIS IS AN AUTOMATED EMAIL -- DO NOT REPLY \*\*\*

Desdiani Desdiani:

Just a gentle reminder of our request for your review of the submission, "COVID-19-associated pulmonary aspergillosis (CAPA): Identification of *Aspergillus* species and determination of antifungal susceptibility profiles: Detection of *Aspergillus* species associated with COVID-19," for The Journal of Infection in Developing Countries. We were hoping to have your response by 2022-10-04, and this email has been automatically generated and sent with the passing of that date.

I believe that you would serve as an excellent reviewer of the manuscript. The submission's abstract is inserted below, and I hope that you will consider undertaking this important task for us.

Please log into the journal web site to indicate whether you will undertake the review or not, as well as to access the submission and to record your review and recommendation.

The review itself is due 2022-10-18.

Submission URL: <https://jdc.org/index.php/journal/reviewer/submission?submissionId=17238&reviewId=26541&key=S8Rf6fpG>

The Journal of Infection in Developing Countries is member of ReviewerCredits. Completing the peer-review you are invited to will automatically transfer your review data to ReviewerCredits, adding it to your certified reviews and assign credits which you may use on ReviewerCredits online store. Find out more [here](#).

You are kindly invited not to claim your review until the review stage is completed.

Thank you for considering this request.

JIDC Central Office The Journal of Infection in Developing Countries

"COVID-19-associated pulmonary aspergillosis (CAPA): Identification of *Aspergillus* species and determination of antifungal susceptibility profiles: Detection of *Aspergillus* species associated with COVID-19"

**Introduction:** Among the co-infectious agents in COVID-19 patients, *Aspergillus* species cause invasive pulmonary aspergillosis (IPA). IPA is difficult to diagnose and is associated with high morbidity and mortality. This study aimed to identify *Aspergillus* spp from sputum and tracheal aspirate (TA) samples of COVID-19 patients and to determine their antifungal susceptibility profiles.

**Methodology:** A total of 50 patients with COVID-19 hospitalized in their intensive care units were included in the study. Identification of *Aspergillus* isolates was performed by phenotypic and molecular methods. ECMM/ISHAM consensus criteria were used for IPA case definitions. The antifungal susceptibility profiles of isolates were determined by the microdilution method.

**Results:** *Aspergillus* spp was detected in 35 (70%) of the clinical samples. Among the *Aspergillus* spp, 20 (57.1%) *A. fumigatus*, 6 (17.1%) *A. flavus*, 4 (11.4%) *A. niger*, 3 (8.6%) *A. terreus*, and 2 (5.7%) *A. welwitschiae* were identified. In general, *Aspergillus* isolates were susceptible to the tested antifungal agents. In the study 9 patients (18%) were diagnosed with possible IPA, 11 (22%) patients were diagnosed with probable IPA, and 15 (30%) patients were diagnosed with *Aspergillus* colonization according to the used algorithms. Serum GM antigen positivity was found in 11 (55%) of the patients diagnosed with IPA (n=20).

*Conclusions:* Our results provide data on the incidence of IPA, identification of *Aspergillus* spp, and its susceptibility profiles in critically ill COVID-19 patients. Prospective studies are needed for a faster diagnosis or antifungal prophylaxis to manage the poor prognosis of IPA and reduce the risk of mortality.

--

The Journal of Infection in Developing Countries

## Re: [JIDC] Submission Review Reminder

---

Dari: desdiani - (desdiani@ymail.com)

Kepada: srubino@jdc.org

Tanggal: Senin, 5 Desember 2022 pukul 07.50 GMT+7

---

Dear Editor JIDC,

I've submitted a manuscript review.  
Thank you.

Best Regards,  
Desdiani Desdiani

Pada Selasa, 29 November 2022 22.16.51 GMT+7, Salvatore Rubino <srubino@jdc.org> menulis:

\*\*\* THIS IS AN AUTOMATED EMAIL -- DO NOT REPLY \*\*\*

Desdiani Desdiani:

Just a gentle reminder of our request for your review of the submission, "COVID-19-associated pulmonary aspergillosis (CAPA): Identification of Aspergillus species and determination of antifungal susceptibility profiles: Detection of Aspergillus species associated with COVID-19," for The Journal of Infection in Developing Countries. We were hoping to have this review by 2022-10-18, and would be pleased to receive it as soon as you are able to prepare it.

Submission URL: <https://jdc.org/index.php/journal/reviewer/submission?submissionId=17238&reviewId=26541&key=2HKVrVWi>

Please confirm your ability to complete this vital contribution to the work of the journal. I look forward to hearing from you.

Salvatore Rubino  
Università degli Studi di Sassari  
srubino@jdc.org

Salvatore Rubino, Editor in Chief JIDC

--

The Journal of Infection in Developing Countries

## [JIDC] Submission Review Reminder

---

Dari: Marina Pekmezovic (marinapekmezovic@gmail.com)

Kepada: desdiani@ymail.com

Tanggal: Rabu, 19 Oktober 2022 pukul 20.54 GMT+7

---

\*\*\* THIS IS AN AUTOMATED EMAIL -- DO NOT REPLY \*\*\*

Desdiani Desdiani:

Just a gentle reminder of our request for your review of the submission, "COVID-19-associated pulmonary aspergillosis (CAPA): Identification of Aspergillus species and determination of antifungal susceptibility profiles: Detection of Aspergillus species associated with COVID-19," for The Journal of Infection in Developing Countries. We were hoping to have this review by 2022-10-18, and would be pleased to receive it as soon as you are able to prepare it.

Submission URL: <https://jidc.org/index.php/journal/reviewer/submission?submissionId=17238&reviewId=26541&key=FCNpYweb>

Please confirm your ability to complete this vital contribution to the work of the journal. I look forward to hearing from you.

Marina Pekmezovic  
marinapekmezovic@gmail.com

--

The Journal of Infection in Developing Countries